the strains detected in Mongolia in 2012. Mapping the amino acid (aa) substitution, four differences (V78A, S159N, S162P and K189Q) are found in Huabei/1/2007 respect to the vaccine strain Ibaraki/1/2007, three in the antigenic site B (top of the protein) and one in E. Comparing the vaccine strain against Heinlongjian/ SS1/2013, two extra aa substitution can be seen (A144T and E198G). Our study support the understanding of the molecular evolution of H3N8 EIV in Asia and will facilitate future investigations of the epidemiology of these viruses because, the EIV strains still evolving in the population. Furthermore, contributes to the monitoring of vaccines the currently available. . 2) BRP titration and validation: after pooling and inactivation with Betapropiolactone, a batch of BRP and SRH/HI antigens will be provided to up to 10 independent collaborative laboratories for SRH and HI titration. Individual titrations will be analysed by the EDQM statistics department in order to define the new FC2 BRP potency titre. Conclusion: the availability of up-to date reference standards is essential to develop, evaluate and standardise the different methods of prevention against EI (e.g. EI vaccines and serological diagnostic tools). This presentation aims to review the multi-stage process of production and establishment of a new horse antiserum BRP specific to the FC2 representative EIV strain, with results currently obtained highlighted and pivotal stages presented and discussed.
